Advances in antiretroviral therapy

Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

(2013) Rochelle P. Walensky et al.   ANNALS OF INTERNAL MEDICINE

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

(2012) Carolina Garrido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection

(2012) Luigia Elzi et al.   ARCHIVES OF INTERNAL MEDICINE

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

(2012) Mark R. Underwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

(2011) Babafemi Taiwo et al.   AIDS

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients

(2011) Joseph Gathe et al.   ANTIVIRAL THERAPY

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

(2011) Jürgen K. Rockstroh et al.   CLINICAL INFECTIOUS DISEASES

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

(2011) Srinivasan Ramanathan et al.   CLINICAL PHARMACOKINETICS

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

(2010) Kathleen E Squires et al.   AIDS

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

(2010) José Moltó et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE